X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership aims to develop and commercialise of Rivalif (rivastigmine) twice weekly transdermal patch in South Korea for the treatment of mild to moderate dementia associated with Alzheimer's disease.
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Rivalif
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Myung In Pharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 05, 2024
Details:
Zepzelca (lurbinectedin) is a DNA-negative allosteric modulator. It is approved for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: Zepzelca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: PharmaMar
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
Rivastigmine MD (rivastigmine) is an acetylcholinesterase inhibitor, transdermal patch. It is approved for the treatment of mild to moderate Alzheimer's Disease.
Lead Product(s): Rivastigmine
Therapeutic Area: Neurology Product Name: Rivastigmine MD
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gensci
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
LY03010 (paliperidone palmitate) Prolonged Release Suspension for Injection is a central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism which isused to treat schizophrenia.
Lead Product(s): Paliperidone Palmitate
Therapeutic Area: Psychiatry/Psychology Product Name: LY03010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
Details:
Rykindo® (risperidone) is an atypical antipsychotic for the treatment of schizophrenia anfd as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults. It acts as combined D2 and 5HT2 receptor antagonist.
Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Product Name: Rykindo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2023
Details:
LY03010 (paliperidone palmitate) injection is a central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism which isused to treat schizophrenia.
Lead Product(s): Paliperidone Palmitate
Therapeutic Area: Psychiatry/Psychology Product Name: LY03010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 28, 2022
Details:
Luye Pharma grants Auriga exclusive distribution and marketing rights for Seroquel® (quetiapine fumarate, immediate release formulation) and Seroquel XR® (extended release formulation) in Singapore.
Lead Product(s): Quetiapine Hemifumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: DCH Auriga
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 13, 2022
Details:
LY03010 (paliperidone palmitate) extended-release injectable suspension is a central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism which isused to treat schizophrenia.
Lead Product(s): Paliperidone Palmitate
Therapeutic Area: Psychiatry/Psychology Product Name: LY03010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2022
Details:
Luye grants ICI Pakistan exclusive rights to distribute Seroquel (quetiapine fumarate, immediate release) and Seroquel XR (extended release formulation), atypical anti-psychotic medicines with antidepressant properties, for schizophrenia & bipolar disorder, in Pakistan.
Lead Product(s): Quetiapine Hemifumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: ICI Pakistan Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 26, 2022
Details:
Zepzelca (lurbinectedin) is a DNA-negative allosteric modulator. It is approved for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: Zepzelca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: PharmaMar
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
